Mo Khan, chief executive of hVIVO, talks to Vox Markets about the huge operational and financial progress the company made in 2023, and why that’s likely to continue into the new year as the group opens its new facility.
Pharmaceutical
Pharma
HVO
hVivo
respiratory syncytial virus
Main Market
AIM Market
Shares
Stocks
Fund Manager
Stocks to Follow
Stock Market
Investing
AIM
Money
Equities
Markets
